Teduglutide
- Generic Name
- Teduglutide
- Brand Names
- Gattex, Revestive
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 197922-42-2
- Unique Ingredient Identifier
- 7M19191IKG
- Background
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogeno...
- Indication
Teduglutide is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
- Associated Conditions
- Short Bowel Syndrome (SBS)
- Associated Therapies
- -
Study of Teduglutide in Japanese Participants With Short Bowel Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Shire
- Target Recruit Count
- 7
- Registration Number
- NCT03663582
- Locations
- 🇯🇵
Hyogo College of Medicine Hospital, Hyogo, Japan
🇯🇵Yokohama Municipal Citizen's Hospital, Yokohama, Japan
🇯🇵Osaka University Hospital, Osaka, Japan
An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT03596164
- Locations
- 🇯🇵
Tohoku University Hospital, Miyagi-Ken, Japan
🇯🇵Osaka University Hospital, Osaka, Japan
🇯🇵Hyogo College of Medicine Hospital, Hyogo, Japan
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 10
- Registration Number
- NCT03571516
- Locations
- 🇬🇧
Royal Manchester Children's Hospital, Manchester, Greater Manchester, United Kingdom
🇫🇷Groupe Hospitalier Pellegrin - Hôpital des Enfants, Bordeaux, Gironde, France
🇫🇷Hopital Jeanne de Flandre - CHRU Lille, Lille, Nord, France
Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients
- First Posted Date
- 2018-06-19
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 25
- Registration Number
- NCT03562130
- Locations
- 🇫🇷
Hôpital Necker - Enfants malades, Paris, France
Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 21
- Registration Number
- NCT03442972
- Locations
- 🇨🇦
Kensington Screening Clinic, Toronto, Ontario, Canada
🇨🇦Toronto General Hopital, Toronto, Ontario, Canada
Plasma Lipoprotein Response to Glucagon-like Peptide-2
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT03422666
- Locations
- 🇨🇦
Toronto General Hopital, Toronto, Ontario, Canada
A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302
- First Posted Date
- 2017-08-31
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Shire
- Target Recruit Count
- 9
- Registration Number
- NCT03268811
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Kagoshima-Ken, Japan
🇯🇵Showa University Hospital, Shinagawa-ku, Tokyo-To, Japan
🇯🇵Akita University Hospital, Akita-shi, Akita-ken, Japan
Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 10
- Registration Number
- NCT02980666
- Locations
- 🇯🇵
Tsukuba University Hospital, Tsukuba, Ibaraki-Ken, Japan
🇯🇵Kyushu University Hospital, Fukuoka-shi, Fukuoka-ken, Japan
🇯🇵Kagoshima University, Kagoshima-shi, Kagoshima-Ken, Japan
Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 29
- Registration Number
- NCT02949362
- Locations
- 🇺🇸
Mattel Children's Hospital UCLA, Los Angeles, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
Teduglutide for Enterocutaneous Fistula (ECF)
- Conditions
- Interventions
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Daniel Dante Yeh
- Target Recruit Count
- 6
- Registration Number
- NCT02889393
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.